Literature DB >> 19369384

Alpha-Synuclein contributes to GSK-3beta-catalyzed Tau phosphorylation in Parkinson's disease models.

Tetyana Duka1, Valeriy Duka, Jeffrey N Joyce, Anita Sidhu.   

Abstract

We have shown in the parkinsonism-inducing neurotoxin MPP(+)/MPTP model that alpha-Synuclein (alpha-Syn), a presynaptic protein causal in Parkinson's disease (PD), contributes to hyperphosphorylation of Tau (p-Tau), a protein normally linked to tauopathies, such as Alzheimer's disease (AD). Here, we investigated the kinase involved and show that the Tau-specific kinase, glycogen synthase kinase 3beta (GSK-3beta), is robustly activated in various MPP(+)/MPTP models of Parkinsonism (SH-SY5Y cotransfected cells, mesencephalic neurons, transgenic mice overexpressing alpha-Syn, and postmortem striatum of PD patients). The activation of GSK-3beta was absolutely dependent on the presence of alpha-Syn, as indexed by the absence of p-GSK-3beta in cells lacking alpha-Syn and in alpha-Syn KO mice. MPP(+) treatment induced translocation and accumulation of p-GSK-3beta in nuclei of SH-SY5Y cells and mesencephalic neurons. Through coimmunoprecipitation (co-IP), we found that alpha-Syn, pSer396/404-Tau, and p-GSK-3beta exist as a heterotrimeric complex in SH-SY5Y cells. GSK-3beta inhibitors (lithium and TDZD-8) protected against MPP(+)-induced events in SH-SY5Y cells, preventing cell death and p-GSK-3beta formation, by reversing increases in alpha-Syn accumulation and p-Tau formation. These data unveil a previously unappreciated role of alpha-Syn in the induction of p-GSK-3beta, and demonstrate the importance of this kinase in the genesis and maintenance of neurodegenerative changes associated with PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19369384      PMCID: PMC2796901          DOI: 10.1096/fj.08-120410

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  59 in total

1.  Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease.

Authors:  José Luna-Muñoz; Francisco García-Sierra; Viviana Falcón; Ivón Menéndez; Laura Chávez-Macías; Raúl Mena
Journal:  J Alzheimers Dis       Date:  2005-09       Impact factor: 4.472

Review 2.  alpha-Synuclein: a potent inducer of tau pathology.

Authors:  James W Geddes
Journal:  Exp Neurol       Date:  2005-04       Impact factor: 5.330

3.  NMDA neuroprotection against a phosphatidylinositol-3 kinase inhibitor, LY294002 by NR2B-mediated suppression of glycogen synthase kinase-3beta-induced apoptosis.

Authors:  Agata Habas; Giorgi Kharebava; Erzsebet Szatmari; Michal Hetman
Journal:  J Neurochem       Date:  2005-11-21       Impact factor: 5.372

4.  Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease.

Authors:  Alan P Kozikowski; Irina N Gaisina; Pavel A Petukhov; Jayalakshmi Sridhar; LaShaunda T King; Sylvie Y Blond; Tetyana Duka; Milan Rusnak; Anita Sidhu
Journal:  ChemMedChem       Date:  2006-02       Impact factor: 3.466

5.  Alpha-Synuclein aggregation in pathological aging and Alzheimer's disease: the impact of beta-amyloid plaque level.

Authors:  Sara M Lippa; Carol F Lippa; Hiroshi Mori
Journal:  Am J Alzheimers Dis Other Demen       Date:  2005 Sep-Oct       Impact factor: 2.035

6.  Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter.

Authors:  Christophe Wersinger; Anita Sidhu
Journal:  Biochemistry       Date:  2005-10-18       Impact factor: 3.162

7.  The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of alpha-Synuclein, in SH-SY5Y neuroblastoma cells.

Authors:  Tetyana Duka; Anita Sidhu
Journal:  Neurotox Res       Date:  2006-08       Impact factor: 3.911

8.  GSK3B polymorphisms alter transcription and splicing in Parkinson's disease.

Authors:  John B J Kwok; Marianne Hallupp; Clement T Loy; Daniel K Y Chan; Jean Woo; George D Mellick; Daniel D Buchanan; Peter A Silburn; Glenda M Halliday; Peter R Schofield
Journal:  Ann Neurol       Date:  2005-12       Impact factor: 10.422

9.  Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism.

Authors:  Tetyana Duka; Milan Rusnak; Robert E Drolet; Valeriy Duka; Christophe Wersinger; John L Goudreau; Anita Sidhu
Journal:  FASEB J       Date:  2006-11       Impact factor: 5.191

Review 10.  GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease?

Authors:  Ana Martinez; Daniel I Perez
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

View more
  109 in total

1.  GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein.

Authors:  J J Credle; J L George; J Wills; V Duka; K Shah; Y-C Lee; O Rodriguez; T Simkins; M Winter; D Moechars; T Steckler; J Goudreau; D I Finkelstein; A Sidhu
Journal:  Cell Death Differ       Date:  2014-11-14       Impact factor: 15.828

2.  Echinacoside Protects Against MPP(+)-Induced Neuronal Apoptosis via ROS/ATF3/CHOP Pathway Regulation.

Authors:  Qing Zhao; Xiaoyan Yang; Dingfang Cai; Ling Ye; Yuqing Hou; Lijun Zhang; Jiwei Cheng; Yuan Shen; Kaizhe Wang; Yu Bai
Journal:  Neurosci Bull       Date:  2016-07-18       Impact factor: 5.203

3.  Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1alpha enhances alpha-synuclein oligomerization and down regulates AKT/GSK3beta signaling pathway in human neuronal cells that inducibly express alpha-synuclein.

Authors:  Abdul Shukkur Ebrahim; Li-Wen Ko; Shu-Hui Yen
Journal:  Neurosci Lett       Date:  2010-02-21       Impact factor: 3.046

4.  BMP2 promotes differentiation of nitrergic and catecholaminergic enteric neurons through a Smad1-dependent pathway.

Authors:  Mallappa Anitha; Nikrad Shahnavaz; Emad Qayed; Irene Joseph; Gudrun Gossrau; Simon Mwangi; Shanthi V Sitaraman; James G Greene; Shanthi Srinivasan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-12-10       Impact factor: 4.052

Review 5.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

6.  Electrophilic adduction of ubiquitin activating enzyme E1 by N,N-diethyldithiocarbamate inhibits ubiquitin activation and is accompanied by striatal injury in the rat.

Authors:  Olga M Viquez; Samuel W Caito; W Hayes McDonald; David B Friedman; William M Valentine
Journal:  Chem Res Toxicol       Date:  2012-08-22       Impact factor: 3.739

7.  Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.

Authors:  D M Vargas; M A De Bastiani; R B Parsons; F Klamt
Journal:  Mol Neurobiol       Date:  2020-11-19       Impact factor: 5.590

Review 8.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

9.  The tau code.

Authors:  Jesús Avila
Journal:  Front Aging Neurosci       Date:  2009-07-30       Impact factor: 5.750

Review 10.  The ubiquitin proteasome system in neuropathology.

Authors:  Norman L Lehman
Journal:  Acta Neuropathol       Date:  2009-07-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.